Brittany Lovely | Authors


Better Prediction of Response to Trastuzumab Deruxtecan Analyzed in HER2-Positive Breast Cancer

December 11, 2020

To identify which patients with HER2-positive breast cancer are most likely to respond to fam-trastuzumab deruxtecan-nxki, investigators used a novel HER2 quantitative continuous score to provide a better objective and quantitative assessment of HER2 expression, data presented during the 2020 San Antonio Beast Cancer Symposium show.

Ublituximab Doublet Bests Chemoimmunotherapy in Chronic Lymphocytic Leukemia

December 07, 2020

In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.